Prospective Study
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Nov 16, 2021; 9(32): 9869-9877
Published online Nov 16, 2021. doi: 10.12998/wjcc.v9.i32.9869
Efficacy of Yiqi Jianpi anti-cancer prescription combined with chemotherapy in patients with colorectal cancer after operation
Zheng Li, Dong-Feng Yin, Wei Wang, Xin-Wei Zhang, Li-Jiang Zhou, Jun Yang
Zheng Li, Graduate School, Liaoning University of Traditional Chinese Medicine, Shenyang 110847, Liaoning Province, China
Dong-Feng Yin, Li-Jiang Zhou, Jun Yang, Oncology Department, The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang 110032, Liaoning Province, China
Wei Wang, Xin-Wei Zhang, Department of Integrated Traditional Chinese and Western Medicine, Liaoning Cancer Hospital and Institute, Shenyang 110042, Liaoning Province, China
Author contributions: Li Z was responsible for study design, collected and analyzed the data, and drafted the manuscript; Wang W collected and analyzed the data and reviewed the manuscript; Zhang XW, Zhou LJ, and Yang J were responsible for date analysis and review of the manuscript; Yin DF was responsible for study co-design, data analysis, and critical review of the manuscript; all authors approved the final version of the manuscript to be submitted.
Institutional review board statement: The study was reviewed and approved by the institutional review board of Liaoning Cancer Hospital and Institute.
Clinical trial registration statement: This study is not registered.
Informed consent statement: All study participants, or their legal guardian, provided written consent prior to study enrollment.
Conflict-of-interest statement: There is no conflict of interest to disclose.
Data sharing statement: There is no additional data available.
CONSORT 2010 statement: The manuscript was checked and revised according to the CONSORT 2010 statement.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Dong-Feng Yin, MD, Chief Doctor, Professor, Oncology Department, The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, No. 33 Beiling Street, Shenyang 110032, Liaoning Province, China. 148003642@qq.com
Received: June 22, 2021
Peer-review started: June 22, 2021
First decision: July 5, 2021
Revised: July 16, 2021
Accepted: August 25, 2021
Article in press: August 25, 2021
Published online: November 16, 2021
Abstract
BACKGROUND

At present, colorectal cancer is routinely treated with adjuvant radiotherapy and chemotherapy postoperatively. The adverse effects (AEs) of chemotherapy usually interrupt the treatment of chemotherapy. Traditional Chinese medicine (TCM) has demonstrated great potential in improving patients' clinical symptoms, regulating the immune function, improving the life quality, and reducing the AEs of chemotherapy.

AIM

To observe the clinical efficacy of Yiqi Jianpi anti-cancer prescription combined with chemotherapy in patients with colorectal cancer after operation.

METHODS

Data from patients diagnosed with colorectal cancer between January 2019 and February 2021 were collected from Liaoning Cancer Hospital and Institute and the Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine. Patients receiving the chemotherapy regimen of capecitabine plus oxaliplatin (CAPOX) after radical resection of colorectal cancer were prospectively collected and randomly divided into an experimental group and a control group. The experimental group was given Yiqi Jianpi anti-cancer prescription combined with the CAPOX regimen, while the control group was given the CAPOX regimen alone. After six cycles of chemotherapy, the scores of TCM symptoms, Karnofsky performance scale (KPS) score, levels of T-cell subsets, and AEs after chemotherapy of the two groups were compared.

RESULTS

A total of 70 patients were randomly divided into either an experimental group (n = 35, no dropout) or a control group (n = 33, with 2 dropouts). Compared with the control group, the experimental group improved significantly (P < 0.05) in scores of TCM symptoms, KPS score, levels of T-cell subsets, and AEs of chemotherapy.

CONCLUSION

Yiqi Jianpi anti-cancer prescription can effectively improve spleen deficiency, regulate the immune function, and alleviate the AEs of chemotherapy, so as to improve the life quality of patients with good therapeutic effects and application prospect in clinical practice.

Keywords: Yiqi Jianpi, Anti-cancer, Postoperative colorectal cancer, Immune function, Life quality, Chemotherapy, Adverse effects

Core Tip: In this study, the authors found that the Yiqi Jianpi anti-cancer prescription can effectively improve spleen deficiency, regulate the immune function, and alleviate the adverse effects (hand-foot skin reaction and gastrointestinal reaction) of chemotherapy, so as to improve the life quality of patients with good therapeutic effects and application prospect in clinical practice.